Select a medication above to begin.
Evista
raloxifene
Black Box Warnings .
Venous Thromboembolism Risk
contraindicated in patients with active or past history of venous thromboembolism due to incr. venous thromboembolism risk
Fatal Stroke Risk
incr. risk of death from stroke in postmenopausal patients with documented coronary heart disease or risk factors for major coronary events; consider risk/benefit in patients with stroke risk
Adult Dosing .
Dosage forms: TAB: 60 mg
osteoporosis prevention, postmenopausal
- [60 mg PO qd]
- Info: calcium and vitamin D supplementation recommended if inadequate intake; D/C tx >72h before surgery with VTE risk
osteoporosis tx, postmenopausal
- [60 mg PO qd]
- Info: calcium and vitamin D supplementation recommended if inadequate intake; D/C tx >72h before surgery with VTE risk
breast CA prevention
- [60 mg PO qd]
- Info: for postmenopausal patients at high risk for invasive breast CA; D/C tx >72h before surgery with VTE risk
renal dosing
- [see below]
- CrCl >50: no adjustment; CrCl <50: not defined, caution advised
- HD/PD: not defined
hepatic dosing
- [see below]
- hepatic impairment: not defined, caution advised
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.